CLAIM AMENDMENTS

1-13. (Cancelled)

14. (Currently amended) A pharmaceutical ~~Pharmaceutical~~ composition comprising (a) a therapeutically effective amount of an active principle ~~for oral use that is in the form of a system which is~~ and (b) a self micro-emulsifying carrier, said self micro-emulsifying carrier ~~self-microemulsifying on contact with an aqueous phase,~~ comprising:

~~a therapeutically effective amount of the said active principle;~~

(i) [[-]] a lipophilic phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with at least one fatty acid chosen from the group ~~comprising~~ consisting of C_8-C_{18} fatty acids;

(ii) [[-]] a surfactant phase comprising a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with caprylic acid (C_8) and capric acid (C_{10});

(iii) a co-surfactant phase comprising at least one ester of a polyvalent alcohol with at least one fatty acid chosen from a group consisting of caprylic esters of propylene glycol;

said surfactant and co-surfactant being in a ~~the~~ ratio by weight ~~TA/CoTA being~~ between 0.2 and 6.[[,]]

~~characterized in that the ester of a polyvalent alcohol with at least one fatty acid in the co-surfactant phase is chosen from the group comprising caprylic esters of propylene glycol.~~

15. (Currently amended) Composition according to Claim 14, ~~characterized in that the~~ wherein said lipophilic phase ~~comprises a mixture of glycerol mono-, di- and triesters and of PEG mono- and diesters with the combination of saturated C_8-C_{18} fatty acids, the said mixture having~~ has an HLB value equal to 14 and it represents ~~representing~~ between 50 and 95% by weight of the composition.

16. (Currently amended) A composition ~~Composition~~ according to claim 14, ~~characterized in that~~ wherein the surfactant phase represents between 1% and 30% by weight of the ~~mixture~~ composition.

17. (Currently amended) A composition ~~Composition~~ according to claim 14, ~~characterized in that~~ wherein the co-surfactant phase represents between 3% and 32% by weight of the ~~mixture~~ composition.

18. (Currently amended) A composition ~~Composition~~ according to claim 14, ~~characterized in that the~~ wherein said active principle is a ~~belongs to the~~ statin ~~family~~.

19. (Currently amended) A composition ~~Composition~~ according to Claim 18, ~~characterized in that the~~ wherein said statin is simvastatin.

20. (Currently amended) A composition ~~Composition~~ according to Claim 19, ~~characterized in that the~~ wherein said simvastatin represents between 0.1% and 6% by weight of the composition ~~and advantageously 4% by weight~~.

21. (Currently amended) A composition ~~Composition~~ according to claim 14, ~~characterized in that it comprises by weight~~ wherein said active principle is simvastatin and wherein said simvastatin represents by weight between 0.1% and 6% of the composition, said lipophilic phase represents by weight between 52% and 70% of the composition, said surfactant phase represents by weight between 5% and 30% of the composition, and said co-surfactant phase is comprised of propylene glycol monocaprylate, wherein propylene glycol monocaprylate represents by weight between 15% and 30% of the composition. ~~:~~

~~between 0.1% and 6% of simvastatin,~~

~~between 52% and 70% of Gélucire® 44/14,~~

~~between 5% and 30% of Labrasol®,~~

~~between 15% and 30% of propylene glycol monocaprylate.~~

22. (Currently amended) A composition ~~Composition~~ according to Claim 21, ~~characterized in that the~~ wherein said propylene glycol monocaprylate ~~consists of Capryol® PGMC representing~~ represents by weight between 15% and 25% ~~by weight~~ of the composition.

23. (Currently amended) A composition ~~Composition~~ according to Claim 21, ~~characterized in that the~~ wherein said propylene glycol monocaprylate ~~consists of Capryol® 90 representing~~ represents by weight between 20% and 30% ~~by weight~~ of the composition.

24. (Currently amended) A composition ~~Composition~~ according to Claim 21, ~~characterized in that the~~ wherein said surfactant and co-surfactant are in a 0.5 ratio by weight ~~TA/CoTA is equal to 0,5~~.

25. (New) A composition according to claim 21, wherein said lipophilic phase has an HLB value of 14.

26. (New) A composition according to claim 21, wherein said lipophilic phase is comprising of lauric macrogolglycerides.

27. (New) A composition according to claim 21, wherein said surfactant phase has an HLB value between 5 and 20.

28. (New) A composition according to claim 21, wherein said surfactant phase is caprylocapric magrogol glyceride.